{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:31:23Z","timestamp":1786570283076,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dmd.2026.100336","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:24:51Z","timestamp":1780154691000},"page":"100336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics and resistance patterns of vancomycin and amikacin in pediatric oncology patients"],"prefix":"10.1016","volume":"54","author":[{"given":"Khalid M.","family":"Alkharfy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitab","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Neyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar Eid","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1781-5191","authenticated-orcid":false,"given":"Rakan Jamal","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dmd.2026.100336_bib1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3390\/diagnostics12081800","article-title":"Diagnosis and management of febrile neutropenia in pediatric oncology patients\u2014a systematic review","volume":"12","author":"Boeriu","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.dmd.2026.100336_bib2","first-page":"1086","article-title":"Update on febrile neutropenia in pediatric oncological patients undergoing chemotherapy","volume":"8","author":"Cennamo","year":"2021","journal-title":"Children (Basel)"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.paed.2019.12.002","article-title":"Febrile neutropenia in paediatric oncology","volume":"30","author":"Davis","year":"2020","journal-title":"Paediatr Child Health (Oxf)"},{"issue":"suppl 1","key":"10.1016\/j.dmd.2026.100336_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jinf.2015.04.026","article-title":"Febrile neutropenia in children treated for malignancy","volume":"71","author":"Barton","year":"2015","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal management of neutropenic fever in patients with cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib6","first-page":"37","article-title":"Management of febrile neutropenia in the era of bacterial resistance","volume":"1","author":"Alp","year":"2013","journal-title":"Ther Adv Infect Dis"},{"issue":"12","key":"10.1016\/j.dmd.2026.100336_bib7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/antibiotics13121197","article-title":"Evaluation of antibiotic resistance mechanisms in Gram-positive bacteria","volume":"13","author":"Rajput","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"10.1016\/j.dmd.2026.100336_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0025-6196(25)09907-0","article-title":"Vancomycin","volume":"52","author":"Geraci","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.dmd.2026.100336_bib9","series-title":"StatPearls [Internet]","article-title":"Vancomycin","author":"Patel","year":"2025"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-024-01459-z","article-title":"A review of vancomycin, gentamicin, and amikacin population pharmacokinetic models in neonates and infants","volume":"64","author":"Albanell-Fern\u00e1ndez","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2026.100336_bib11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/antibiotics10101182","article-title":"Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine","volume":"10","author":"Gijsen","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.dmd.2026.100336_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"issue":"10","key":"10.1016\/j.dmd.2026.100336_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40262-018-0641-x","article-title":"Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses","volume":"57","author":"Illamola","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmd.2026.100336_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01781-17","article-title":"Amikacin pharmacokinetic-pharmacodynamic analysis in pediatric cancer patients","volume":"62","author":"Alhadab","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.dmd.2026.100336_bib15","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1128\/AAC.02564-13","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2026.100336_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28132","article-title":"Pharmacokinetics and population pharmacokinetics in pediatric oncology","volume":"67","author":"Sassen","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.dmd.2026.100336_bib17","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s00431-023-05103-z","article-title":"Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program","volume":"182","author":"Velarde-Salcedo","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","article-title":"Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen","volume":"17","author":"Kato","year":"2017","journal-title":"Drugs R D"},{"issue":"11","key":"10.1016\/j.dmd.2026.100336_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1186\/s12879-025-11400-9","article-title":"Association of vancomycin trough levels, AUC and AUC\/MIC ratios with clinical outcomes in patients with enterococcal bacteremia: a prospective cohort study","volume":"25","author":"Sel","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.dmd.2026.100336_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.6061\/clinics\/2012(07)21","article-title":"Clinical pharmacokinetics of vancomycin in the neonate: a review","volume":"67","author":"Pacifici","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100336_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10928-025-09982-7","article-title":"Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities","volume":"52","author":"Cha","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bcp.15895","article-title":"ChatGPT in pharmacometrics? Potential opportunities and limitations","volume":"90","author":"Cloesmeijer","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10928-024-09921-y","article-title":"Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM","volume":"51","author":"Shin","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12887-023-04288-4","article-title":"Age-associated augmented renal clearance and low BMI trigger suboptimal vancomycin trough concentrations in children with haematologic diseases: data of 1453 paediatric patients from 2017 to 2022","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Pediatr"},{"issue":"2","key":"10.1016\/j.dmd.2026.100336_bib50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/jgo.2016.09.17","article-title":"Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function","volume":"8","author":"Gong","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"suppl 1","key":"10.1016\/j.dmd.2026.100336_bib28","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1182\/blood-2024-193894","article-title":"Outcome of oncologic pediatric patients presenting with febrile neutropenia after implementation of the standard of procedure in the outpatient department","volume":"144","author":"Malvestiti","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.dmd.2026.100336_bib29","article-title":"Bacterial isolates and characteristics of children with febrile neutropenia on treatment for cancer at a tertiary hospital in Western Kenya","volume":"10","author":"Kipchumba","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.dmd.2026.100336_bib30","article-title":"Impact of using different renal function estimation equations on vancomycin dosing","author":"Gratac\u00f3s","year":"2025","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"10.1016\/j.dmd.2026.100336_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2025.100970","article-title":"Using KeGFR for vancomycin dosing when renal clearance is acutely changing: a simulation study in a retrospective cohort","volume":"7","author":"Bairy","year":"2025","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib32","first-page":"83","article-title":"Prescribing empiric antibiotics for febrile neutropenia: compliance with institutional febrile neutropenia guidelines","volume":"6","author":"Naeem","year":"2018","journal-title":"Pharmacy (Basel)"},{"issue":"2","key":"10.1016\/j.dmd.2026.100336_bib33","first-page":"504","article-title":"Clinical spectrum and sensitivity pattern of isolates in pediatric febrile neutropenic patients of acute lymphoblastic leukemia","volume":"14","author":"Lodhi","year":"2020","journal-title":"Pak J Med Health Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100336_bib34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.15537\/smj.2023.44.5.20220915","article-title":"Estimating the prevalence of pediatric hematological malignancies in Al-Madinah Al-Munawwarah, Saudi Arabia","volume":"44","author":"Alhajori","year":"2023","journal-title":"Saudi Med J"},{"key":"10.1016\/j.dmd.2026.100336_bib35","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.2147\/IDR.S369909","article-title":"Alarming antibiotic resistance in pediatric oncology patients: a three-year prospective cohort study from Oman","volume":"15","author":"Al Battashi","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"2","key":"10.1016\/j.dmd.2026.100336_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46889\/JCIM.2023.4203","article-title":"Evaluation of antibiotic resistance in pediatric patients suffering from cancer","volume":"4","author":"Akhtar","year":"2023","journal-title":"J Clin Immunol Microbiol"},{"key":"10.1016\/j.dmd.2026.100336_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1480952","article-title":"Bloodstream infections in pediatric hematology\/oncology patients: a single-center study in Wuhan","volume":"14","author":"Murshed","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13756-023-01332-x","article-title":"Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study","volume":"12","author":"Meschiari","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"10.1016\/j.dmd.2026.100336_bib39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jpids\/piz064","article-title":"Limiting vancomycin exposure in pediatric oncology patients with febrile neutropenia may be associated with decreased vancomycin-resistant Enterococcus incidence","volume":"9","author":"Karandikar","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"6","key":"10.1016\/j.dmd.2026.100336_bib40","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/jac\/dky075","article-title":"Duration of exposure to multiple antibiotics is associated with increased risk of VRE bacteraemia: a nested case-control study","volume":"73","author":"Gouliouris","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.dmd.2026.100336_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2334-7-24","article-title":"Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic review","volume":"7","author":"de Bruin","year":"2007","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.dmd.2026.100336_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/502016","article-title":"Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer","volume":"23","author":"Husni","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100336_bib43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2217\/fmb-2017-0143","article-title":"Staphylococcus epidermidis: a major player in bacterial sepsis?","volume":"12","author":"Otto","year":"2017","journal-title":"Future Microbiol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100336_bib44","first-page":"715","article-title":"Staphylococcus epidermidis septicemia in children with leukemia and lymphoma","volume":"138","author":"Friedman","year":"1984","journal-title":"Am J Dis Child"},{"issue":"1","key":"10.1016\/j.dmd.2026.100336_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-023-08058-6","article-title":"Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country","volume":"23","author":"Joudeh","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.dmd.2026.100336_bib46","first-page":"12","volume":"72","author":"Alzu'bi","year":"2024"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12288-011-0076-0","article-title":"Piperacillin-tazobactum plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in neutropenic patients with hematological malignancies","volume":"27","author":"Ghalaut","year":"2011","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"12","key":"10.1016\/j.dmd.2026.100336_bib48","first-page":"1995","article-title":"Glomerular filtration rate assessment in children","volume":"9","author":"Jan\u010di\u010d","year":"2022","journal-title":"Children (Basel)"},{"issue":"8","key":"10.1016\/j.dmd.2026.100336_bib51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamaoncol.2016.1236","article-title":"Jaundice (hyperbilirubinemia) in cancer","volume":"2","author":"Subbiah","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100336_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00897-21","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in infants, children, and adolescents with augmented renal clearance","volume":"65","author":"He","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100336_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.dmd.2026.100336_bib54","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100336_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:07:42Z","timestamp":1786568862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0090955626006057"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100336","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics and resistance patterns of vancomycin and amikacin in pediatric oncology patients","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100336"}}